News
US FDA Grants Orphan Drug Designation to Lakefront’s Gamgertamig for Pemphigus
Developed by Lakefront in collaboration with Gilead Sciences, gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the US FDA for the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia.
imphoenix82
- August 25, 2026
- 0 Comments
- 37 Views
-
